Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Neoplasms × Anastrozole × Clear all

Phase

Status

Completed 6 Not yet recruiting 2 Terminated 1 Recruiting 1 Enrolling by invitation 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 21 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 1 Patient Compliance 1 Neoplasms 1 Breast Neoplasms, Male 1 Breast Neoplasm Female 1 Breast Cancer Metastatic 1 Advanced Breast Cancer 1

Interventions

Gemcitabine 29 pembrolizumab 22 Cyclophosphamide 19 Paclitaxel 17 Irinotecan 17 Carboplatin 17 Fluorouracil 16 Docetaxel 16 Capecitabine 16 Leucovorin 13 Bevacizumab 12 fludarabine 11 Oxaliplatin 11 Everolimus 11 Pemetrexed 10 Erlotinib Hydrochloride 10 Dexamethasone 10 Rituximab 9 Cisplatin 9 Blood Specimen Collection 9 venetoclax 8 Cetuximab 8 Trastuzumab 7 Nivolumab 7 Sunitinib 6 Ipilimumab 6 Epoetin Alfa 6 Bortezomib 6 Azacitidine 6 trametinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01151215 2014-07-25

MINT

AstraZeneca

Phase 2 Terminated

482 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡